Related Experiment Video
Updated: Aug 25, 2025
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Ginsenoside Rg3, a promising agent for NSCLC patients in the pandemic: a large-scale data mining and systemic
Zhenjie Zhuang1, Qianying Chen1, Xiaoying Zhong1
1Guangzhou University of Chinese Medicine, Guangzhou, China.
Introduction:
Non-small cell lung cancer (NSCLC) patients are particularly vulnerable to the Coronavirus Disease-2019 (COVID-19). Currently, no anti-NSCLC/COVID-19 treatment options are available. As ginsenoside Rg3 is beneficial to NSCLC patients and has been identified as an entry inhibitor of the virus, this study aims to explore underlying pharmacological mechanisms of ginsenoside Rg3 for the treatment of NSCLC patients with COVID-19.
Methods:
Based on a large-scale data mining and systemic biological analysis, this study investigated target genes, biological processes, pharmacological mechanisms, and underlying immune implications of ginsenoside Rg3 for NSCLC patients with COVID-19.
Results:
An important gene set containing 26 target genes was built. Target genes with significant prognostic value were identified, including baculoviral IAP repeat containing 5 (BIRC5), carbonic anhydrase 9 (CA9), endothelin receptor type B (EDNRB), glucagon receptor (GCGR), interleukin 2 (IL2), peptidyl arginine deiminase 4 (PADI4), and solute carrier organic anion transporter family member 1B1 (SLCO1B1). The expression of target genes was significantly correlated with the infiltration level of macrophages, eosinophils, natural killer cells, and T lymphocytes. Ginsenoside Rg3 may benefit NSCLC patients with COVID-19 by regulating signaling pathways primarily involved in anti-inflammation, immunomodulation, cell cycle, cell fate, carcinogenesis, and hemodynamics.
Conclusions:
This study provided a comprehensive strategy for drug discovery in NSCLC and COVID-19 based on systemic biology approaches. Ginsenoside Rg3 may be a prospective drug for NSCLC patients with COVID-19. Future studies are needed to determine the value of ginsenoside Rg3 for NSCLC patients with COVID-19.
Insights
Ginsenoside Rg3 shows promise for treating non-small cell lung cancer (NSCLC) patients with COVID-19 by impacting inflammation and immunity. Further research is needed to confirm its therapeutic potential in this vulnerable population.
Area of Science:
- Pharmacology
- Oncology
- Virology
- Immunology
Background:
- Non-small cell lung cancer (NSCLC) patients face increased risk from Coronavirus Disease-2019 (COVID-19).
- No specific treatments currently exist for NSCLC patients with COVID-19.
- Ginsenoside Rg3 demonstrates benefits for NSCLC and acts as a viral entry inhibitor.
Purpose of the Study:
- To explore the pharmacological mechanisms of ginsenoside Rg3 for treating NSCLC patients concurrently infected with COVID-19.
- To identify key genes and biological pathways influenced by ginsenoside Rg3 in this context.
Main Methods:
- Large-scale data mining and systemic biological analysis were employed.
- Target genes, biological processes, and immune implications were investigated.
- Prognostic value of identified target genes was assessed.
Main Results:
- A set of 26 target genes, including BIRC5, CA9, EDNRB, GCGR, IL2, PADI4, and SLCO1B1, with prognostic significance was identified.
- Gene expression correlated with immune cell infiltration (macrophages, eosinophils, NK cells, T lymphocytes).
- Ginsenoside Rg3 appears to modulate pathways related to anti-inflammation, immunomodulation, cell cycle, cell fate, carcinogenesis, and hemodynamics.
Conclusions:
- Ginsenoside Rg3 presents potential as a therapeutic agent for NSCLC patients with COVID-19.
- The study offers a systemic biology strategy for drug discovery in this dual condition.
- Further clinical studies are warranted to validate the efficacy of ginsenoside Rg3.
